Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 134,986 251,929 319,053 656,089
Total Sell Value $11,097,511 $21,508,551 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 9 19 27 56
End Date 2024-04-04 2024-01-02 2023-07-04 2022-07-04

   
Records found: 1285
  Page 35 of 52  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-05-08 4 AS $93.17 $465,850 D/D (5,000) 238,496     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-05-08 4 OE $17.33 $86,650 D/D 5,000 243,496     -
   Meier Richard A Director   –       •      –    2017-05-05 4 OE $17.33 $129,975 D/D 7,500 34,260     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2017-05-05 4 AS $99.00 $444,114 D/D (4,486) 51,532     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2017-05-05 4 OE $28.23 $162,879 D/D 4,486 55,030     -
   Davis George Eric EVP, General Counsel   •       –      –    2017-05-05 4 AS $100.34 $250,852 D/D (2,500) 85,251     -
   Davis George Eric EVP, General Counsel   •       –      –    2017-05-05 4 OE $38.59 $96,475 D/D 2,500 87,751     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-05-05 4 AS $99.00 $495,000 D/D (5,000) 238,496     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-05-05 4 OE $17.33 $86,650 D/D 5,000 243,496     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2017-05-02 4 AS $96.74 $29,215 D/D (302) 51,532     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2017-04-28 4 A $70.30 $10,897 D/D 155 26,826     -
   Baffi Robert EVP, Technical Operations   •       –      –    2017-04-28 4 A $70.30 $21,232 D/D 302 147,793     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2017-04-28 4 A $70.30 $21,232 D/D 302 140,494     -
   Mueller Brian SVP, Corporate Controller   •       –      –    2017-04-28 4 A $70.30 $18,982 D/D 270 18,350     -
   Davis George Eric EVP, General Counsel   •       –      –    2017-04-28 4 A $70.30 $21,232 D/D 302 85,251     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-04-28 4 A $70.30 $21,232 D/D 302 238,496     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2017-04-28 4 A $70.30 $21,232 D/D 302 51,834     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-04-27 4 AS $95.72 $478,600 D/D (5,000) 238,194     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-04-27 4 OE $17.33 $86,650 D/D 5,000 243,194     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-04-25 4 AS $94.00 $470,000 D/D (5,000) 238,194     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-04-25 4 OE $17.33 $86,650 D/D 5,000 243,194     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-04-04 4 OE $14.39 $43,170 D/D 3,000 238,194     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2017-03-29 4 AS $89.15 $346,794 D/D (3,890) 51,532     -
   Davis George Eric EVP, General Counsel   •       –      –    2017-03-22 4 A $0.00 $0 D/D 11,220 84,949     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2017-03-22 4 A $0.00 $0 D/D 19,790 140,192     -
  1285 Records found
  Previous  30  31  32  33  34  35  36  37  38  39  Next   
  Page 35 of 52
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us